Member Info for Astrad

Shouldn't we have had an RNS about this? Or have I missed one?

Ah no worries! I was busy down a rabbit hole looking at Polish waste water monitoring ;) so probably best you intervened

That was supposed to be a laughing emoji...should have known better than to try to be down with the kids

Ah, I bow to your superior insight into the great man's life ??

I almost bought some 4D this time last year - think the price was about 25p. Ended up buying a few others which did well but not this well.

Haven't been able to contemplate getting in having missed the big rise but re-researched over the last week or so and still such a compelling proposition. Ridiculous pipeline any of which could strike gold, then there's the platform itself and Merck clearly very interested.

Will be moving 5-10% of portfolio in on Monday with serious expectations of a multi bag this year. Very interested to watch how the daq listing plays out.

Anyone else wondering why GB is tweeting about the weather in Warsaw?

Sounds fantastic and as expected you are way ahead of me - thanks for the reply Mr Brandon.

Interested to see what the routes to market are. The Harry's razors (valuation ~£1bn) model largely cut out any middlemen initially to build subscribers, but not easy to do. The modern way of course is to get a handful of influencers to give it a try...of course the nice thing about Skin Trust is it's not just for people who want to spend hundreds a month on skincare.

SAE been on my radar a couple of weeks but only done serious research this weekend.

The numbers on Uskmouth alone Vs the market cap seem insane - the market seems to be pricing in a pretty high likelihood of failure (certainly >50%) and that's ignoring the pelleting (which I get could also fall by the wayside if the stations don't work) and the tidal (which is OK a longer term play but potentially huge).

CEO debate is interesting: new guy is clearly a big hitter and surely wouldn't come aboard if things were really about to go down the pan. Even if this sort of business is super fashionable I think he must be confident Uskmouth is going to work.

Will be taking a small position in the morning and maybe adding over coming weeks. I think this looks well under valued and removal of risk and uncertainty over Uskmouth in the coming months will prompt a re rate.

Been thinking a bit about Skin Trust over the last couple of days.

Everyone but everyone wants their product "as a service" and wants recurring revenues. I'm certain GB and team well ahead of me on this, but I wonder whether the market is really selling one-off £50 (say) skin evaluations, with a list of recommendations that come back.

The end goal must be to get people on a subscription, where perhaps you pay £50 up front and get a year's updates, then it's a couple of quid a month (or whatever) to stay on the database and get new product launches evaluated for your skin characteristics?

Don't know how feasible this is, and the up front testing alone will be a big deal of course. But interesting to speculate.

As an aside there was a guessing game re 2021 revenue guidance. I think GB would view £10m as pretty much standstill based on H2 2020 plus MWG and he does seem very excited so I'll take a punt at £18m which would be ridiculous but then again...

Massive news IMO. Walkers could be the ones moving forward with their testing. Happy days.

The RNS says £4m revenue *growth* right?

Interesting chat on here, some very realistic views imo.

I'm strongly pro-vaxx (is that a thing?) but have my doubts about take up of something rushed to market without normal process. It's not like taking an experimental drug when you're dying: you're asking people who are healthy to take some risk, in the hope of a preventative benefit. Honestly I think a 25% unvaccinated gap in the population is optimistic.

Then there's the question about whether it's even a good strategy, given we don't know how long these will provide protection for, or whether they will prevent transmission or just infection and to what degree.

I think most sensible governments (maybe not ours) should be buying in SNG001 as an obvious backup, and deploying it to anyone who tests positive with symptoms. So fully on board here and expecting significant news probably January. People forget winter hasn't really started.

I get that it's not been the easiest few weeks even for those invested long term and who are here for the whole portfolio now under the DVRG roof.

But then I read something like the below and think Christ, even allowing for the vaccination optimism (which I think is massively overblown and premature, though I get why everyone wants it to work!) there is a hell of a lot of cash being thrown at this, DVRG is quite right to chase a bit of the rainbow.

UK government to pump up to £43bn into Covid testing - https://on.ft.com/2IiGejG via @FT

I can understand why people are getting het up about costs - the daily £4 and the cost of the readers. But I think it's a classic case of not understanding the scale of state spending. If everyone in the country had a daily test (unnecessary, not everyone is going somewhere every day) you're talking what £70bn/year if gov funded it all. Have a quick look at what we are currently spending on furlough, unemployment benefits, moonshot, whatever.

People also seem hung up on the inequality angle. This isn't anything new. How do we solve it for other medical situations? Well, we give out free prescriptions to those who can't afford them, for example. So reality might look like the government subsidising some of the cost (let's say half - does £2/test feel more palatable, for a cost to gov of perhaps £25bn/year?). Or, they might make them available for free to people on low incomes. There are other options too: you could mandate tests for hospitality workers, for example, and the cost of 10/20 staff in a pub being tested would be recouped pretty quickly.

Agree the presentation wasn't as slick as it might have been but I think this is a case of people not understanding a transformational technology. I may be proven wrong in time but I'm not selling any of my shares.

https://www.theguardian.com/world/2020/sep/18/canada-coronavirus-saliva-test-swirl-gargle-spit-children

Yes I had a quick look on their website when the RNS came out. One of those businesses no one has really heard of but fingers in all sorts of pies.

Seem like a good fit, I noted their food division talks specifically about healthier ingredients etc so hoping they will be in the door with plenty of the right manufacturers.

Also like the global reach. Possible US food regs easier to cut through than Europe or something but no doubt they will have global partnerships that will want MicroSalt.

Hate to bang on about this but their annual report says they held at 31/12/19 and if they exercised surely GGP have to RNS it. They RNS'd the last MTR exercise in 2017. It's possible I suppose that they haven't but seems strange.

Alternatives I guess are that MTR sold the warrants (seems like MTR should RNS that), or that the website is wrong. To be honest any event with the warrants post 31/12/19 would seem newsworthy from MTR's point of view given the share price movements, so unless someone can point me to that RNS I still think the website is wrong and they continue to hold them.

Great RNS, shares up 40% admittedly from a ridiculous price. So much more to come on all fronts and if we can hold these gains and hit the risers board then a lot more people re going to be looking into Tek and realising what a cracking opportunity they are at these prices. When we get some figures on sales under this new Salarius partnership - perhaps an update by the end of the year? - people are going to really realise how cheap Tel is.

If they'd exercised warrants wouldn't GGP have RNS'd it? Personally think GGP have further to run and MTR won't exercise for a while (what have they got, another six months or something?)

Popped in here to see reaction to the RNS but board is silent even though it's a cracker - clearly been holding back the good stuff to underpin the NASDAQ launch.

SLN360 approval, SLN124 dosing, second target milestone payment... Should fly on this news.